Verrica Pharmaceuticals (VRCA) said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union.

The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate to support the filing and that no additional Phase 3 trials are required, Verrica said.

The company plans to submit the application as early as Q4 2026.

YCANTH, which contains cantharidin, is the first and only Food and Drug Administration-approved treatment for molluscum contagiosum in adults and children aged two years and older.

Verrica Pharmaceuticals were down 8.25% in Monday after hours trading.